Abstract. Goniothalamin, a plant bioactive styrly-lactone, possesses many biological activities. In the present study, the anticancer effect of goniothalamin on human breast cancer cell line SK-BR-3 was investigated. The results showed that goniothalamin induced nuclear condensation, DNA fragmentation, apoptotic bodies and mitochondrial dysfunction as determined by JC-1 staining. Goniothalamin also increased the Bax/Bcl-2 ratio and expression of cleaved caspase-7, cleaved caspase-9 and cleaved PARP, but decreased Bcl-2 expression. In addition, goniothalamin induced apoptosis via p-JNK1/2 and p-p38 upregulation and inhibited cell survival via p-ERK1/2 and p-Akt downregulation. Notably, goniothalamin induced autophagy through upregulation of Atg7, Atg12-Atg5 conjugation and LC3II. The increased p-p38 and p-JNK1/2 and decreased p-Akt may lead to autophagy induction. Therefore, goniothalamin promoted apoptosis associated with autophagy induction in SK-BR-3 cells through p-p38 and p-JNK1/2 upregulation and p-Akt downregulation. The present study indicated that goniothalamin may be further used as a potential therapeutic candidate or may offer an alternative treatment for breast cancer.
Introduction
Breast cancer is the most common invasive cancer and is the leading cause of death among females worldwide (1) . In patients who are younger than 50 years, chemotherapy increases the survival rate up to 15 years (10%), but in older women the increase is only 3% (2) . However, the long-term side-effects of chemotherapy substantially affect the quality of life of these patients (3) .
Apoptosis or programmed cell death is an essential physiological process that plays a critical role in development, tissue homeostasis and elimination of damaged cells. The morphological changes of apoptosis are due to the action of caspases (4). Apoptosis was initially described by its morphological characteristics, including cell shrinkage, membrane blebbing, chromatin condensation and nuclear fragmentation (5) . Biochemical features associated with apoptosis include internucleosomal cleavage of DNA, phosphatidylserine (PS) externalization and plasma membrane changes (6) .
Three types of cell death have been identified based on morphological criteria, including type I (apoptosis), type II (autophagic cell death) and type III (necrosis) cell death. The autophagic pathway involves the degradation of subcellular components. This process includes the formation of cytoplasmic double membrane-bound vacuoles (autophagosomes), which sequester cytosolic cargo for delivery to the lysosomes (7) . The autophagy-related (Atg) proteins and microtubule-associated protein 1 light chain 3 (LC3) are major proteins involved in the processes of autophagy (8) . The overexpression of the autophagic signal has been reported in various forms of cell death under certain experimental conditions resulting in autophagy-dependent cell death (9) .
Goniothalamin, a plant bioactive styrly-lactone found in the family Annonaceae, has been mainly isolated from the genus Goniothalamus (10) . In the present study, we used goniothalamin extracted from Goniothalamus macrophyllus that is found in the Southern part of Thailand and is known by the local name, ̔Ching Dok Diao̓ or ̔Rajchakru̓ (11) . Goniothalamin has been shown to exhibit antimicrobial, antifungal (12) and insecticidal activity (13) . Indeed, it was reported that goniothalamin inhibited cell proliferation and induced cytotoxicity in a variety of cancer cells such as cervical (14) , gastric, kidney (15) , leukemia (16) , ovarian, melanoma, colon (17) , liver (18) , lung (19) and breast (20) cancer cells. Moreover, goniothalamin has been shown to possess anticancer and apoptosis-inducing properties in several types of cancer. However, the effects of goniothalamin on human HER2-overexpressing breast cancer, which grows and spreads more rapidly than other breast cancer types, have not yet been studied. Therefore, we aimed to verify the hypothesis that goniothalamin could inhibit the growth of the human breast cancer SK-BR-3 cell line through induction of apoptosis.
Our study demonstrated that goniothalamin increased the levels of cleaved-caspase-7 and -9 and cleaved PARP, decreased Bcl-2 expression and increased the Bax/Bcl-2 ratio.
Goniothalamin induces apoptosis associated with autophagy activation through MAPK signaling in SK-BR-3 cells
JC-1 staining revealed that goniothalamin induced mitochondrial transmembrane dysfunction. The results also showed that goniothalamin downregulated levels of phosphorylated ERK1/2 and phosphorylated Akt. Moreover, goniothalamin induced apoptosis through upregulation of phosphorylated JNK1/2 and p38 in the SK-BR-3 cells. In addition, goniothalmin induced autophagy through upregulation of Atg7, Atg12-5 conjugation and LC3II in the SK-BR-3 cells. Our results demonstrated that goniothalamin induced apoptosis through MAPK signaling associated with autophagy induction in the SK-BR-3 cells. Cell culture. Breast cancer cell line SK-BR-3 was obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). The cells were maintained as a monolayer in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (PAA Laboratories, Pasching, Austria). The cells were cultured in 5% CO 2 at 37˚C, and after reaching ~90% confluency, the cells were subcultured and the medium was replaced 2-3 times/week.
Materials and methods

Materials
Cell proliferation and cell viability assays. The cytotoxicity of goniothalamin was determined by cell proliferation analysis using MTT assay. The cells were seeded in a 96-well plate (5x10 3 cells/well) and allowed to grow for 24 h. The cells were then treated with goniothalamin at various concentrations, whereas the control group was treated with DMSO. After incubation for 24 h, 100 µl of 0.5 mg/ml MTT solution was added to each well, and the plate was further incubated for 2 h at 37˚C. The supernatant was removed, and 100 µl of DMSO was added to each well to solubilize the water insoluble purple formazan crystals. The absorbance was measured using a microplate reader at 570 nm (Multiskan EX; Thermo Electron Corp., Vantaa, Finland), and the IC 50 value was calculated using the software GraphPad Prism 3.03 (GraphPad Software, Inc., San Diego, CA, USA).
The effect of goniothalamin on cell viability at different times and doses was determined. The cells were treated with goniothalamin at various concentrations of 5, 10, 15 and 20 µg/ml, whereas the control group was treated with DMSO. After incubation for 3, 6, 9, 12 and 24 h, cell viability was determined by the MTT assay. Survival percentage (%) of the cells was calculated relative to the control. Cell viability was assessed in three independent experiments.
Nuclear morphological staining with Hoechst 33342. SK-BR-3 cells were seeded at 3x10 5 /35-mm dish for 24 h. The cells were treated with 20 µg/ml goniothalamin for 3, 6, 9 and 12 h. As control, the cells were treated with 0.02% DMSO for 24 h. Subsequently, the cells were stained with 10 µM Hoechst 33342 for 30 min at 37˚C and examined under a fluorescence microscope (IX73; Olympus, Tokyo, Japan).
Cell cycle analysis. To examine apoptosis, the SK-BR-3 cells were treated with 20 µg/ml goniothalamin. The cells were harvested after drug treatment and washed with phosphatebuffered saline (PBS). The cells were fixed with 70% ethanol at 4˚C for >1 h. Then, the cells were stained according to the manufacturer's instructions (Guava Cell Cycle ® reagent from Merck Millipore Corp., Merck KGaA. The DNA content was observed using the Guava EasyCyte™ flow cytometer and GuavaSoft™ software (Merck Millipore Corp., Merck KGaA).
Measurement of mitochondrial membrane potential (∆Ψm).
The ∆Ψm was determined using the potential sensitive dye JC-1, which is a lipophilic cation that is incorporated into the mitochondrial membrane. The cells were seeded at 3x10 5 /35-mm dish for 24 h and treated with 20 µg/ml goniothalamin for 3, 6 and 9 h, and the control cells were treated with 0.02% DMSO. The cells were then stained with 5 µg/ ml of JC-1 in the dark at 37˚C for 15 min before analysis by fluorescence microscopy (IX73).
Western blot analysis. The SK-BR-3 cells were seeded at 3x10 5 /35-mm dish for 24 h, and treated with 20 µg/ml goniothalamin, and harvested at designated time points. Then, the cells were lysed with RIPA lysis buffer (50 mM Tris-HCL, pH 7.5, 5 mM EDTA, 250 mM NaCl, 0.5% Triton X-100) supplemented with 10 mM PMSF and Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics GmbH, Mannheim, Germany). The supernatants were prepared by centrifugation, and the protein content was determined using a protein assay kit (Bio-Rad Laboratories, USA). The total protein extracts were separated by 8-12% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (GE Healthcare, Buckinghamshire, UK) for 1-2 h at 100 V using a Mini Trans-Blot Cell (Bio-Rad Laboratories). The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline and Tween-20 (TBST) (10 mM Tris, pH 7.5, 150 mM NaCl and 0.1% Tween-20) for 1 h at room temperature and incubated overnight at 4˚C with the primary antibody (Cell Signaling Technology, Beverly, MA, USA). Membranes were washed three times in TBST buffer, followed by incubation for 1 h at room temperature with the corresponding HRP-linked secondary antibodies. The specific protein bands were detected by chemiluminescent HRP substrate (Merck Millipore Corp., Merck KGaA) and detected under a chemiluminescent imaging system (GeneGnome Gel Documentation; Synoptics Ltd., Cambridge, UK).
Statistical analysis. All data presented were obtained from at least three independent experiments and are presented as mean ± standard deviation (SD). Statistical significance was assessed by one-way analysis of variance (ANOVA). Statistical analysis was performed using SPSS statistical software package (version 11.5) also carried out using the software GraphPad Prism 3.03 (GraphPad Software, Inc.). The western blotting band intensity was quantified by ImageJ densitometer. An asterisk indicates that the experimental values are significantly different from those of the control (p<0.05).
Results
Goniothalamin inhibits cell viability and induces apoptosis in SK-BR-3 human breast cancer cells.
The antiproliferative activity of goniothalamin in the SK-BR-3 cells was determined by MTT assay. The IC 50 value was 10±0.45 µg/ ml. Goniothalamin inhibited cell viability in a dose-and time-dependent manner. Treatment of SK-BR-3 cells with 20 µg/ml goniothalamin for 12 h reduced cell viability to ~20% comparing with that noted in the control cells (Fig. 1A) .
To determine the antiproliferation and cell death induction mediated by goniothalamin, Hoechst 33342 staining was carried out. The results showed that goniothalamin induced chromatin condensation and DNA fragmentation, characteristics of apoptotic cells (Fig. 1B) . Effect of goniothalamin on cell cycle distribution. The effect of goniothalamin on the cell cycle showed that goniothalamin alone did not increase the sub-G1 population. In contrast, the goniothalamin-treated cells showed an increase in the sub-G1 population to 3.02 and 34.84% after treatment with 20 µg/ml goniothalamin for 12 and 24 h, respectively (Fig. 1C) .
Effect of goniothalamin on ΔΨm. During apoptosis, several key events occur in the mitochondria. Bax forms oligomers on the mitochondrial membrane leading to changes in electron transport and loss of ΔΨm. JC-1 is a cytofluorimetric, lipophilic cationic dye that can selectively enter into mitochondria and reversibly change color from green to red as the membrane potential increases. In healthy cells with high ΔΨm, JC-1 spontaneously forms complexes known as J-aggregates with intense red fluorescence. In contrast, in apoptotic or unhealthy cells with low ΔΨm, JC-1 remains in the monomeric form, which shows only green fluorescence. The ratio of green to red fluorescence is dependent only on the ΔΨm. The results showed that SK-BR-3 cells treated with goniothalamin for 3, 6 and 9 h had an increased green/red ratio, while the control cells showed red fluorescence (Fig. 2) indicating that goniothalamin induced the loss of ΔΨm in the SK-BR-3 cells.
Effect of goniothalamin on the expression of Bcl-2 family proteins, caspase-7 and -9, and cleaved PARP activation.
The Bcl-2 family proteins have expanded significantly and are composed of both pro-apoptotic and anti-apoptotic molecules. To determine whether goniothalamin induces apoptosis through the mitochondrial apoptotic pathway, we examined the expression of the Bcl-2 family proteins. As shown in Fig. 3A , goniothalamin decreased Bcl-2 expression at 6 h, while it increased the Bax/Bcl-2 ratio at 9 h (Fig. 3B) . These results indicate that goniothalamin induced apoptosis through the mitochondrial pathway.
Caspase expression was also determined by western blot analysis. The results showed that goniothalamin induced caspase-9 and -7 cleavage after 3 and 6 h of treatment (Fig. 3C) . The maximal induction of cleaved caspase-9 was at 6 h, and then was markedly decreased at 9 and 12 h. In addition, cleaved caspase-7 was maximally activated at 6 h and was decreased at 9 and 12 h, which was correlated with the expression of the proform. Ferguson et al showed that apoptosis induction in MCF-7 was independent of caspase-9 expression. Caspase-7 expression was not correlated with caspase-9 expression for apoptosis induction in MCF-7 cells (21). Hakem et al also showed that caspase-9 deficiency could not protect cells from apoptosis induced by α-CD95 and could not protect caspase-3 activation in vivo (22) . Moreover, goniothalamin induced cleaved PARP activation downstream of caspase. The results indicated that goniothalamin induced apoptosis mediated by caspases and PARP through the intrinsic apoptosis pathway (via caspase-9).
Effect of goniothalamin on expression of Akt. Akt plays a key role in multiple cellular processes such as cell growth, cell proliferation, transcription and cell migration. PDK activates Akt by phosphorylation at Thr308 and Ser473. The results showed that levels of phosphorylated Akt (p-Akt) at Thr308 and Ser473 were decreased as well as phosphorylated PDK1 (p-PDK1) at Ser241 (Fig. 4) , suggesting that goniothalamin inhibited cell survival by downregulation of p-Akt expression in the SK-BR-3 cells.
Effect of goniothalamin on expression of MAPKs. MAPK pathways are evolutionarily conserved kinases, which link extracellular signals to the machinery that controls fundamental cellular processes such as growth, proliferation, differentiation, migration and apoptosis. There is a three-step kinase module in which a MAPK is activated upon phosphorylation by a MAPKK, which in turn is activated when phosphorylated by a MAPKKK. Our results showed an increase in phosphorylated JNK1/2 (p-JNK1/2) and phosphorylated p38 (p-p38) expression, but a decrease in phosphorylated ERK1/2 (p-ERK1/2) expression in the SK-BR-3 cells following goniothalamin treatment (Fig. 5A) . In addition, a MEK1/2 inhibitor (U0126) simultaneously blocked p-ERK1/2 indicating that goniothalamin inhibited cell survival through ERK signaling (Fig. 5B) . These results demonstrated that goniothalamin induced apoptosis by inhibiting cell survival through p-ERK1/2 activation.
Effect of goniothalamin on autophagy induction.
For autophagy induction, the protein level of LC3II, which is a protein marker of autophagy, was determined. As shown in Fig. 6 , the LC3II level was increased in the SK-BR-3 cells treated with goniothalamin. In addition, the levels of Atg7 and Atg12-Atg5 conjugation were upregulated while no effect was noted on Beclin-1. These results demonstrated that goniothalmin induced autophagy in the SK-BR-3 cells through the upregulation of LC3II, Atg7 and Atg12-Atg5 conjugation.
Discussion
Recent research has demonstrated the cytotoxicity and antitumor properties of goniothalamin against various human tumor cell lines such as A-549 (lung carcinoma), HL-60 (promyelocytic leukemia) and SGC-7901 (stomach cancer) (23) . It also induced apoptosis in cancer cells such as HeLa (cervical cancer), HT29 (colon cancer) (24), Ca9-22 (oral cancer) (25), HepG2 (hepatoblastoma), and invasive breast carcinoma MDA-MB-231 cell lines (26) . However, the mechanisms of apoptosis induction in breast cancer SK-BR-3 cells have not yet been reported.
The results showed that goniothalamin inhibited SK-BR-3 cell growth in a time-and dose-dependent manner with an IC 50 value of 10±0.45 µg/ml (Fig. 1A) . To confirm apoptosis induction, we investigated characteristic morphological changes including cell shrinkage, membrane blebbing, chromatin condensation and formation of apoptotic bodies. Hoechst 33342 staining revealed condensed chromatin and apoptotic bodies in the SK-BR-3 cells following treatment with goniothalamin (Fig. 1B) . The population of sub-G1 cells indicated apoptotic cell death (Fig. 1C) . Furthermore, the effect of goniothalamin on the mitochondrial membrane potential (ΔΨm) dysfunction in SK-BR-3 cells was detected by increased green/red fluorescence ratio at 3 h (Fig. 2) . Loss of the ΔΨm and release of sequestered pro-apoptotic proteins from the intermembranous space into the cytosol stimulates apoptosome formation followed by activation of caspase-9 (27) .
It is well-known that the apoptosis signaling pathway consists of two main pathways: extrinsic and intrinsic pathways. Our results showed that goniothalamin decreased Bcl-2 expression (Fig. 3A) and increased the Bax/Bcl-2 ratio (Fig. 3B) in SK-BR-3 cells. These events suggested that goniothalamin induced apoptosis through the intrinsic pathway. Inayat-Hussain et al reported that goniothamin did not alter the level of Bcl-2 expression in Jurkat cells. Then, Bcl-2-overexpressed Jurkat cells were used to demonstrate the effects of Bcl-2 on cell death by MTT assay. They found that Bcl-2 overexpression did not protect the cells from the cytotoxic effects of goniothalamin (28) . This discrepancy is likely due to the different cell types examined, as Jurkat cells (T-lymphocyte) are suspension cells whereas SK-BR-3 (breast cancer) are adherent cells. In addition, they possess different receptors on the cell surface; thus they responded differently. Another study showed that goniothalamin induced apoptosis via Bcl-2 inactivation by JNK1/2. JNK1/2 phosphorylated Bcl-2 (Ser70, Ser87 and Thr69) leading to inactivation of the anti-apoptotic function (29) .
The control and regulation of these apoptotic mitochondrial events occurs through members of the Bcl-2 family proteins. Anti-apoptotic Bcl-2 proteins exert their activity by binding to the pro-apoptotic members Bax and Bak, preventing mitochondrial damage (30) . Thus, decreased Bcl-2 was associated with mitochondrial dysfunction and led to apoptosis. To confirm whether the apoptosis induction by goniothalamin was caspase-dependent, we examined the active forms of caspases by western blot analysis. The effect of goniothalamin on PARP activity was also determined. The results indicated that treatment with 20 µg/ml goniothalamin induced cleaved caspase-9, and -7, and cleaved PARP expression in the SK-BR-3 cells (Fig. 3C) . The initiator caspase-9 causes the activation of the effector caspases (-3, -6 and -7), which cleave vital substrates including PARP, resulting in cellular death. PARP plays an important role in DNA repair and the activation of cellular defense mechanisms against DNA damage. PARP is inactivated by caspase cleavage via caspase-3 or -7. The size of the cleaved fragments (89 kDa) can provide insight into which enzyme is responsible for the cleavage, and can be useful in determining which cell death pathway has been activated (31) . In HeLa cells, goniothalamin was reported to induce apoptosis through caspase-9 activity (32). Moreover, goniothalamin induced caspase-3 and cleaved PARP expression in breast cancer MDA-MB-231 cells treated with 30 µM goniothalamin for 48 h (26) .
Akt upregulation is likely to be viewed as a compensatory protective mechanism of cells for escaping death, and the fully active Akt mediates numerous cellular functions leading to cell survival (33) . Our results showed that goniothalamin inhibited cell survival via p-Akt downregulation (Fig. 4) , which corresponded with a previous study that the anticancer mechanism of RA-V was related to the blockage of PDK1 and Akt interaction leading to apoptosis induction (34) .
The MAPK kinase family plays a critical role in cell survival and cell death. Conventional MAPKs in mammalian cells include ERK1/2, JNK1/2 and p38, which are activated through a specific phosphorylation cascade. Active ERK1/2 phosphorylates numerous cytoplasmic and nuclear targets, including kinases, phosphatases, transcription factors and cytoskeletal proteins (35) . It is well-known that ERK1/2 promotes cell survival, while JNK1/2 and p38 induce apoptosis. Dunn et al reported that the presence of the ERK signaling pathway depends on the particular cell type, and progresses to regulate proliferation, differentiation, survival, migration, angiogenesis and chromatin remodeling (36) . ERK1/2 can also promote cell survival by upregulation of anti-apoptotic molecules via enhancement of their activities or activation of their transcription. JNK1/2 can activate transcriptional factors including c-Jun and AP1, whereas their tumor-suppressive functions are probably related to their pro-apoptotic activity (37) . In the present study, goniothalamin downregulated p-ERK1/2 at 6 h, but upregulated p-JNK1/2 and p-p38 at 3 and 6 h, respectively (Fig. 5A) . Indeed, we also confirmed that goniothalamin in combination with U0126, an ERK inhibitor, suppressed p-ERK1/2 activation (Fig. 5B) . These results demonstrated that goniothalamin induced apoptosis via p-JNK1/2 and p-p38 upregulation and inhibited cell survival via p-ERK1/2 downregulation.
Notably, goniothalamin showed autophagy induction through upregulation of Atg7, Atg12-Atg5 conjugation and LC3II (Fig. 6 ) in a time-and dose-dependent manner indicating autophagic cell death associated with the elevation of autophagosome formation. These results were supported by a previous study that Atg12-Atg5 conjugation and the conversion of LC3I to LC3II indicate autophagic activity (38) . In addition, another function of Atg12 is to stimulate mitochondrial apoptosis by inactivating Bcl-2 and Mcl-1 (39) . Therefore, our findings showed that goniothalamin induced apoptosis and autophagy which are processes of programmed cell death and interplay with each other (40) . The Atg family and LC3 are key proteins involved in the autophagy signaling pathway. The conversion of LC3I (16 kDa) to LC3II (14 kDa) is used as a common indicator of autophagy detection (41) . In addition, our results showed that goniothalamin induced p-p38 and p-JNK1/2 upregulation and p-Akt downregulation in the SK-BR-3 cells. These results correlated with previous reseach that found that baicalin induced autophagy accompanied by downregulation of the p-Akt (Ser473) level leading to increased Atg5, Atg7 and Atg12 and then the conversion of LC3I to LC3II and finally autophagy induction (42) . Increased p-p38 leading to inhibition or induction of autophagy depends on the cellular context and cell type (43) . Alisertib was reported to increase the p-p38 level correlated with highly accumulated LC3II in MCF-7 and MDA-MB-231 cells (44) . Furthermore, graphene quantum dots (GQDs) significantly increased p-p38 which was correlated with increased Beclin-1 and LC3II (43) . In addition, increased p-JNK1/2 activation occurred upstream of the autophagy induction when cells were starved (45) .
Furthermore, p-JNK1/2 activation led to Bcl-2 phosphorylation at Thr69, Ser70 and Ser87 which dissociated Bcl-2 from Beclin-1 leading to autophagy progression. Activation of p-JNK1/2 induces FoxOs nuclear localization and increases ATG gene transcription (46) . Thus, goniothalamin induced apoptosis through an increase in cleaved caspase-9, cleaved caspase-7, p-JNK1/2 and p-p38 activation as well as p-ERK1/2 and p-Akt suppression. In addition, p-p38 and p-JNK1/2 upregulation and Akt downregulation may lead to autophagy.
In conclusion, goniothalamin induced apoptosis associated with autophagy through p-p38 and p-JNK1/2 upregulation and Akt downregulation in SK-BR-3 cells. Our findings imply that goniothalamin may be used as an anticancer drug candidate for the treatment of human breast cancer.
